Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Retained Earnings (2023 - 2025)

Historic Retained Earnings for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $4.1 billion.

  • Genmab A's Retained Earnings rose 2081.37% to $4.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 billion, marking a year-over-year increase of 2081.37%. This contributed to the annual value of $4.1 billion for FY2025, which is 2081.37% up from last year.
  • As of Q4 2025, Genmab A's Retained Earnings stood at $4.1 billion, which was up 2081.37% from $4.0 billion recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Retained Earnings peaked at $4.1 billion during Q4 2025, and registered a low of $2.7 billion during Q4 2023.
  • In the last 3 years, Genmab A's Retained Earnings had a median value of $3.6 billion in 2025 and averaged $3.6 billion.
  • In the last 5 years, Genmab A's Retained Earnings surged by 2393.13% in 2024 and then surged by 2081.37% in 2025.
  • Genmab A's Retained Earnings (Quarter) stood at $2.7 billion in 2023, then rose by 23.93% to $3.4 billion in 2024, then increased by 20.81% to $4.1 billion in 2025.
  • Its last three reported values are $4.1 billion in Q4 2025, $4.0 billion for Q3 2025, and $3.6 billion during Q2 2025.